Nothing Special   »   [go: up one dir, main page]

EP0954324A4 - Vaccins a peptides cycliques destines au traitement et a la prevention du diabete - Google Patents

Vaccins a peptides cycliques destines au traitement et a la prevention du diabete

Info

Publication number
EP0954324A4
EP0954324A4 EP97917819A EP97917819A EP0954324A4 EP 0954324 A4 EP0954324 A4 EP 0954324A4 EP 97917819 A EP97917819 A EP 97917819A EP 97917819 A EP97917819 A EP 97917819A EP 0954324 A4 EP0954324 A4 EP 0954324A4
Authority
EP
European Patent Office
Prior art keywords
diabetes
prevention
treatment
cyclic peptide
peptide vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97917819A
Other languages
German (de)
English (en)
Other versions
EP0954324A1 (fr
Inventor
Eva-Pia Reich
Shrikant Deshpande
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anergen Inc
Original Assignee
Anergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anergen Inc filed Critical Anergen Inc
Publication of EP0954324A1 publication Critical patent/EP0954324A1/fr
Publication of EP0954324A4 publication Critical patent/EP0954324A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A01K2267/025—Animal producing cells or organs for transplantation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0325—Animal model for autoimmune diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Obesity (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
EP97917819A 1996-04-03 1997-04-02 Vaccins a peptides cycliques destines au traitement et a la prevention du diabete Withdrawn EP0954324A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1479096P 1996-04-03 1996-04-03
US14790P 1996-04-03
PCT/US1997/005461 WO1997036601A1 (fr) 1996-04-03 1997-04-02 Vaccins a peptides cycliques destines au traitement et a la prevention du diabete

Publications (2)

Publication Number Publication Date
EP0954324A1 EP0954324A1 (fr) 1999-11-10
EP0954324A4 true EP0954324A4 (fr) 2000-11-02

Family

ID=21767765

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97917819A Withdrawn EP0954324A4 (fr) 1996-04-03 1997-04-02 Vaccins a peptides cycliques destines au traitement et a la prevention du diabete

Country Status (5)

Country Link
EP (1) EP0954324A4 (fr)
JP (1) JP2000509022A (fr)
AU (1) AU713067B2 (fr)
CA (1) CA2250814A1 (fr)
WO (1) WO1997036601A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1838348B1 (fr) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Anticorps du peptide beta-amyloide humanises utilises dans l'amelioration de la cognition
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8613920B2 (en) 2007-07-27 2013-12-24 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0286447A2 (fr) * 1987-04-09 1988-10-12 The Board Of Trustees Of The Leland Stanford Junior University Méthode et composés pour le traitement prophylactique des maladies autoimmunes
WO1993014126A1 (fr) * 1992-01-17 1993-07-22 Medical Research Council Antigene de classe ii du complexe d'histocompatibilite majeure utilise dans un vaccin contre un virus d'immunodeficience

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986007464A1 (fr) * 1985-06-14 1986-12-18 Genetic Systems Corporation Procedes d'identification d'alleles associes a un risque accru de diabete

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0286447A2 (fr) * 1987-04-09 1988-10-12 The Board Of Trustees Of The Leland Stanford Junior University Méthode et composés pour le traitement prophylactique des maladies autoimmunes
WO1993014126A1 (fr) * 1992-01-17 1993-07-22 Medical Research Council Antigene de classe ii du complexe d'histocompatibilite majeure utilise dans un vaccin contre un virus d'immunodeficience

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9736601A1 *

Also Published As

Publication number Publication date
JP2000509022A (ja) 2000-07-18
AU713067B2 (en) 1999-11-25
CA2250814A1 (fr) 1997-10-09
EP0954324A1 (fr) 1999-11-10
AU2605097A (en) 1997-10-22
WO1997036601A1 (fr) 1997-10-09

Similar Documents

Publication Publication Date Title
HUP9901109A3 (en) Peptide immunogens for vaccination against and treatment of allergy
HU9602310D0 (en) Urease-based vaccine and treatment for helicobacter infection
EP1010705A4 (fr) Derives tetrapeptides cycliques et leur utilisation medicinale
HK1022835A1 (en) Pharmaceutical composition for treatment of diabetes
HUP9904361A3 (en) Use of isobutylgaba and its derivatives for the treatment of pain
GB9617021D0 (en) Novel peptides for treatment of inflammation and shock
ZA977745B (en) Transdermal delivery of peptides
EP1117429A4 (fr) Vaccins contenant des peptides issus du recepteur de chimiokine permettant de traiter et de prevenir le diabete
GB9808840D0 (en) Treatment of depression and pharmaceutical preparations therefor
EP0954324A4 (fr) Vaccins a peptides cycliques destines au traitement et a la prevention du diabete
PL339085A1 (en) Recombinative expression of insulin peptide c
EP0970965A4 (fr) Peptides cycliques et leur utilisation medicinale
IL121329A (en) Pharmaceutical composition for the treatment of cancer comprising somatostatin2 and other peptides
IL112681A0 (en) Opioid peptides for the treatment of pain and use thereof
EP0969852A4 (fr) Therapie par combinaison d'agents pour le traitement du diabete et de l'obesite
EP1009433A4 (fr) Composition therapeutique et procede de traitement
EP0910655A4 (fr) Vaccins servant a traiter les lymphomes et la leucemie
GB9611500D0 (en) Prevention and treatment of oral conditions with peptides having anti-adherence activity
EP1207895A4 (fr) Peptide et analogues peptidiques destines au traitement et a la prevention du diabete
AU3762397A (en) Treatment and prevention of helicobacter infection
ZA975500B (en) Peptides for prevention and treatment of infection
ZA951440B (en) Novel opiold peptides for the treatment of pain and use thereof
AU3084297A (en) Novel peptides for prevention and treatment of infection
GB9618290D0 (en) Treatment of diabetes
EP1015559A4 (fr) Serfine-1 (rasp-1) associee a la regeneration humaine et methodes d'utilisation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981023

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20000915

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 33/06 A, 7A 61K 38/12 B, 7A 61K 38/16 B, 7C 07K 14/74 B, 7C 07K 14/47 B

17Q First examination report despatched

Effective date: 20010426

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20011107

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1023514

Country of ref document: HK